Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report)’s stock price rose 9.7% during mid-day trading on Tuesday . The company traded as high as $4.51 and last traded at $4.51. Approximately 1,412 shares changed hands during mid-day trading, an increase of 200% from the average daily volume of 470 shares. The stock had previously closed at $4.11.
Molecular Partners Trading Up 9.7 %
The business has a fifty day moving average price of $4.73 and a 200 day moving average price of $5.64.
Molecular Partners Company Profile
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Read More
- Five stocks we like better than Molecular Partners
- Low PE Growth Stocks: Unlocking Investment Opportunities
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- 3 Monster Growth Stocks to Buy Now
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Investing In Automotive Stocks
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
